Metraipolis › archive › dc_e87bb5a0af01

Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model — Europe PMC PMID:42955934

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42955934
DOI
10.1371/journal.pone.0361593
License (as archived)
solo-consultazione
Archived
2026-10-31T21:56:39.020Z
SHA-256 of the archived text
22c6862b9206b4bcff577ebdf3a4b6d741896f69579665c2fe7703a0966f4382
Stable URL of this page
https://metraipolis.com/documento/dc_e87bb5a0af01

How to cite

Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model — Europe PMC PMID:42955934 — Europe PMC (en), https://europepmc.org/article/MED/42955934 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e87bb5a0af01 (Metraipolis archive dc_e87bb5a0af01, sha256 22c6862b9206b4bcff577ebdf3a4b6d741896f69579665c2fe7703a0966f4382)
BibTeX
@misc{dce87bb5a0af01,
  title = {Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model — Europe PMC PMID:42955934},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42955934},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e87bb5a0af01; sha256 22c6862b9206b4bcff577ebdf3a4b6d741896f69579665c2fe7703a0966f4382},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42955934. Agents can read the archived copy with the MCP tool read_document.